Braver Wealth Management Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Braver Wealth Management reduced its stake in Abbott Laboratories by 0.69% during the most recent quarter end. The investment management company now holds a total of 105,517 shares of Abbott Laboratories which is valued at $4,428,548 after selling 735 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Jul 13, 2016.Abbott Laboratories makes up approximately 0.74% of Braver Wealth Management’s portfolio.

Other Hedge Funds, Including , Gofen Glossberg Il boosted its stake in ABT in the latest quarter, The investment management firm added 11,584 additional shares and now holds a total of 457,494 shares of Abbott Laboratories which is valued at $19,201,023. Abbott Laboratories makes up approx 0.79% of Gofen Glossberg Il’s portfolio.Fisher Asset Management reduced its stake in ABT by selling 3,026 shares or 19.63% in the most recent quarter. The Hedge Fund company now holds 12,387 shares of ABT which is valued at $519,882.Northstar Group boosted its stake in ABT in the latest quarter, The investment management firm added 4 additional shares and now holds a total of 10,253 shares of Abbott Laboratories which is valued at $430,318. Abbott Laboratories makes up approx 0.32% of Northstar Group’s portfolio.

Abbott Laboratories closed down -0.01 points or -0.02% at $42.09 with 75,24,201 shares getting traded on Monday. Post opening the session at $42.05, the shares hit an intraday low of $41.81 and an intraday high of $42.229 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.